首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   47926篇
  免费   3431篇
  国内免费   1350篇
耳鼻咽喉   433篇
儿科学   1049篇
妇产科学   575篇
基础医学   3750篇
口腔科学   1592篇
临床医学   5578篇
内科学   10822篇
皮肤病学   1158篇
神经病学   2008篇
特种医学   1963篇
外科学   3886篇
综合类   7301篇
一般理论   4篇
预防医学   5901篇
眼科学   907篇
药学   3322篇
  39篇
中国医学   1863篇
肿瘤学   556篇
  2023年   960篇
  2022年   1588篇
  2021年   2245篇
  2020年   2241篇
  2019年   1890篇
  2018年   1812篇
  2017年   1692篇
  2016年   1600篇
  2015年   1582篇
  2014年   3448篇
  2013年   3511篇
  2012年   2805篇
  2011年   3121篇
  2010年   2481篇
  2009年   2395篇
  2008年   2350篇
  2007年   2229篇
  2006年   1875篇
  2005年   1746篇
  2004年   1357篇
  2003年   1205篇
  2002年   1005篇
  2001年   951篇
  2000年   759篇
  1999年   569篇
  1998年   516篇
  1997年   430篇
  1996年   297篇
  1995年   395篇
  1994年   349篇
  1993年   247篇
  1992年   253篇
  1991年   232篇
  1990年   190篇
  1989年   205篇
  1988年   185篇
  1987年   169篇
  1986年   140篇
  1985年   175篇
  1984年   203篇
  1983年   161篇
  1982年   142篇
  1981年   153篇
  1980年   114篇
  1979年   136篇
  1978年   112篇
  1977年   102篇
  1976年   103篇
  1975年   94篇
  1974年   73篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
DNA损伤是衰老相关疾病领域的研究热点, 可引起细胞周期停滞、凋亡, 加快个体衰老速度、增加衰老相关疾病的患病风险。本文将从细胞衰老和个体衰老两个层面阐述其与衰老之间的研究进展, 并综述其与衰老常见相关疾病(肿瘤、心血管疾病、阿尔茨海默病)及早衰综合征的关系, 为抗衰老研究和临床干预衰老相关疾病提供理论依据。  相似文献   
2.
王付超  林乐岷 《安徽医药》2022,26(11):2171-2174
真空辅助乳腺活检系统( VABB)由美国食品与药品监督管理局于 1995年批准应用于乳腺肿物的活检。该系统包括内外套针、旋切刀、传送装置、真空抽吸泵、控制器及相关软件等组成。 VABB可在多种影像学引导下(乳腺超声、 MRI、X线)对乳腺病灶切除活检。起初 VABB系统主要应用于乳腺病灶的活检,如早期乳腺癌的诊断。由于 VABB通过影像学引导下精确完整切除病灶,能够获得足够量的组织样本进行病理学检查,因此广泛应用于良性乳腺疾病的治疗,如良性乳腺肿瘤的切除、乳腺炎、乳腺整形手术等,成为乳腺微创手术的重要手段。  相似文献   
3.
目的结合文献回顾观察Aicardi-Goutières综合征(AGS)影像学表现。方法回顾性分析3例经基因检测证实的AGS患儿,患儿月龄分别为3、5、8个月,均接受颅脑MR检查,其中1例(病例3)接受颅脑CT检查,结合文献分析其颅脑MRI及CT表现。结果颅脑MRI显示,病例1双侧侧脑室、双侧额颞部脑外间隙增宽;病例2未见明显异常;病例3脑萎缩,双侧侧脑室前角旁异常呈T1WI等信号、T2WI及T2-液体衰减翻转恢复(T2-FLAIR)序列呈稍高信号。颅脑CT显示病例3脑萎缩,双侧基底核区、双侧侧脑室前角旁钙化,双侧侧脑室前角旁低密度灶。结论颅内钙化、脑萎缩和脑白质营养不良为AGS常见影像学表现。  相似文献   
4.
5.
6.
AimThis review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021.Data synthesisThe trials included in this review are related to hypertension onset age and risk for future cardiovascular disease, reliability of different blood pressure monitoring methods, role of exercise-induced hypertension, treatment of hypertension in patients with SARS-CoV-2 infection, management of hypertension high-risk patient groups, e.g., in the elderly (≥80 years) and patients with atrial fibrillation, and the interplay between nutrition and hypertension, as well as recent insights into renal denervation for treatment of hypertension.ConclusionsHypertension onset age, nighttime blood pressure levels and a riser pattern are relevant for the prognosis of future cardiovascular diseases. The risk of coronary heart disease appears to increase linearly with increasing exercise systolic blood pressure. Renin-angiotensin system blockers are not associated with an increased risk for a severe course of COVID-19. In elderly patients, a risk-benefit assessment of intensified blood pressure control should be individually evaluated. A J-shaped association between cardiovascular disease and achieved blood pressure could also be demonstrated in patients with atrial fibrillation on anticoagulation. Salt restriction and lifestyle modification remain effective options in treating hypertensive patients at low cardiovascular risk. Sodium glucose co-transporter 2 inhibitors and Glucagon-like peptide-1 receptor agonists show BP-lowering effects. Renal denervation should be considered as an additional or alternative treatment option in selected patients with uncontrolled hypertension.  相似文献   
7.
Co-stimulatory molecules are key mediators in the regulation of immune responses and knowledge of its different families, structure, and functions has improved in recent decades. Understanding the role of co-stimulatory molecules in pathological processes has allowed the development of strategies to modulate cellular functions. Currently, modulation of co-stimulatory and co-inhibitory molecules has been applied in clinical applications as therapeutic targets in diseases and promising results have been achieved.  相似文献   
8.
9.
Alzheimer’s disease (AD) is a multifactorial neurodegenerative disorder. Cardiometabolic and genetic risk factors play an important role in the trajectory of AD. Cardiometabolic risk factors including diabetes, mid-life obesity, mid-life hypertension and elevated cholesterol have been linked with cognitive decline in AD subjects. These potential risk factors associated with cerebral metabolic changes which fuel AD pathogenesis have been suggested to be the reason for the disappointing clinical trial results. In appreciation of the risks involved, using search engines such as PubMed, Scopus, MEDLINE and Google Scholar, a relevant literature search on cardiometabolic and genetic risk factors in AD was conducted. We discuss the role of genetic as well as established cardiovascular risk factors in the neuropathology of AD. Moreover, we show new evidence of genetic interaction between several genes potentially involved in different pathways related to both neurodegenerative process and cardiovascular damage.  相似文献   
10.
BackgroundRecent guidelines for the treatment of moderate or severe ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG) have changed. This study assessed the real-world impact of changing guidelines on the management of IMR during CABG over time. We hypothesized that the utilization of mitral valve repair for IMR would decrease over time, whereas mitral valve replacement for severe IMR would increase.MethodsPatients undergoing CABG in a statewide collaborative database (2011-2020) were stratified by severity of IMR. Trends in mitral valve repair or replacement were evaluated. To account for differences of the patients, propensity score–matched analyses were used to compare patients with and without mitral intervention.ResultsA total of 11,676 patients met inclusion criteria, including 1355 (11.6%) with moderate IMR and 390 (3.3%) with severe IMR. The proportion of patients undergoing mitral intervention for moderate IMR decreased over time (2011, 17.7%; 2020, 7.5%; Ptrend = .001), whereas mitral replacement for severe IMR remained stable (2011, 11.1%; 2020, 13.3%; Ptrend = .14). Major morbidity was higher for patients with moderate IMR who underwent mitral intervention (29.1% vs 19.9%; P = .005). In a propensity analysis of 249 well-matched pairs, there was no difference in major morbidity (29.3% with mitral intervention vs 23.7% without; P = .16) or operative mortality (1.2% vs 2.4%; P = .5).ConclusionsConsistent with recent guideline updates, patients with moderate IMR were less likely to undergo mitral repair. However, the rate of replacement for severe IMR did not change. Mitral intervention during CABG did not increase operative mortality or morbidity.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号